A death in a China-based, brain-directed gene-editing trial is rekindling questions about oversight for first-in-human personalized therapies. Reporting describes the case of a 6-year-old girl treated at Xinhua Hospital in Shanghai using a base-editing approach aimed at correcting a single DNA variant. The incident has prompted renewed scrutiny of how regulators evaluate safety and efficacy evidence when trials move quickly from laboratory design to patient-specific interventions. Families and experts are now calling for clearer accountability and stronger guardrails for clinical governance. For developers working in precision gene therapy, the case reinforces the need for tightly defined trial protocols, monitoring, and transparent reporting frameworks before broadening access to next-generation editing modalities.